Business Context and Reporting Period
Company: Matinas Biopharma Holdings, Inc. (MTNB)
Filing Type: Form 8-K (Current Report)
Date of Report: August 10, 2020
Reporting Period: Quarter ended June 30, 2020
This filing serves as a notification that the Company issued a press release on August 10, 2020, announcing its financial results for the second quarter of 2020. The full text of the press release is included as Exhibit 99.1.
Key Financial Metrics
The provided Form 8-K text acts as a cover document and does not contain specific numerical data regarding revenue, profit, cash flow, margins, debt, or liquidity. These figures are contained within the referenced press release (Exhibit 99.1), which is not included in the input text.
Source data does not provide clear values for financial metrics in this specific document.
Material Changes
No material changes or comparative financial data are detailed in the body of this Form 8-K. The filing solely references the issuance of the quarterly results announcement.
Guidance, Outlook, and Risks
Management Commentary: The filing confirms the release of Q2 2020 results but does not include specific management commentary, forward-looking guidance, or risk factors within the text provided.
Legal Disclaimer: The filing explicitly states that the information in this report and its exhibits shall not be deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liabilities of that Section, nor is it incorporated by reference in other filings unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated August 10, 2020) for actual revenue, net loss, and cash position figures.
- Verify the Company's cash runway and burn rate as disclosed in the full press release.
- Check for any updates on clinical trial progress or regulatory milestones mentioned in the full announcement.
- Confirm the status of any outstanding debt or financing activities referenced in the detailed results.